ArticleBreast cancer research and treatment2026
Clinical and imaging factors associated with prolonged ablation time in radiofrequency ablation for early-stage breast cancer.
Article in Breast cancer research and treatment, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
purposeRadiofrequency ablation (RFA) is a minimally invasive treatment for selected patients with early-stage breast cancer, but ablation time varies substantially. We investigated clinical, imaging, procedural, and pathological factors associated with prolonged ablation time.
methodsWe retrospectively analyzed 72 patients who underwent breast RFA at a single institution between April 2024 and November 2025. Clinical variables, ultrasonographic tumor characteristics, mammography-based background breast density, ultrasonography-based puncture-site breast density, initial impedance, maximum power, and temperature were evaluated. Exploratory pathological assessment of stromal predominance was performed in 48 patients.
resultsThe median ablation time was 649.5 s (IQR 508.8-879.5). Ablation target size, ultrasonographic tumor dimensions, background density, puncture-site density (p < 0.001), and maximum power were positively associated with ablation time, whereas initial impedance showed a negative correlation. Puncture-site density and initial impedance were strongly inversely correlated (r = -0.716, p < 0.001). Mammography-based background density and ultrasonography-based puncture-site density showed substantial agreement (60/72, 83.3%) and strong ordinal correlation (Spearman r = 0.838, p < 0.001). In multivariable analysis, ablation target size (β = 60.26 s/mm, p = 0.003), initial impedance conditional on puncture-site density (β = 2.89 s/Ω, p = 0.015), and puncture-site density (β = 388.33 s/category, p < 0.001) were independently associated with prolonged ablation time.
conclusionAblation time is influenced by tumor size, local tissue density, impedance, and possibly stromal predominance. Local ultrasonographic assessment complements mammographic density for procedure-specific RFA planning, although prospective validation is required.
Indexed as
Identifiers
42521911What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.